Taehong Park

5PUBLICATIONS
30CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthNanotoxicology, health and safetyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 02, 2026
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer.

|Apr 26, 2024
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.

Min Ho Park, Jae Hong Seo, Jung Ho Park

|Mar 07, 2023
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.

Justin Stebbing, Yauheni Baranau, Valery Baryash

|Feb 09, 2023
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.

Jae-Cheol Jo, Youngwoo Jeon, DaJung Kim

|Mar 10, 2019
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.

Sang-Heon Cho, Seunghoon Han, Jong-Lyul Ghim

Pageof 1

Frequent Collaborators

4 joint publications

KeumYoung Ahn

3 joint publications

Hyungseok Baek

2 joint publications

Hana Ju

1 joint publications

Min Ho Park